Literature DB >> 1846388

Protection against zosteriform spread of herpes simplex virus by monoclonal antibodies.

J C Mester1, J C Glorioso, B T Rouse.   

Abstract

The in vivo protective role of herpes simplex virus (HSV-1)-specific antibody was analyzed using monoclonal antibodies (MAbs) reactive with discrete antigenic sites on glycoproteins B, C, and D (gB, gC, gD) in the murine zosteriform spread model of HSV-1. All of the anti-gC and anti-gD MAbs, and one of four anti-gB MAbs (B6) were protective. The in vitro abilities of the MAbs to neutralize HSV-1 and mediate antibody-dependent cellular cytotoxicity (ADCC) against HSV-1-infected cells were examined as potential mechanistic correlates to in vivo protection. All animals given MAbs at high ADCC unit doses were protected. Some but not all mice given MAbs at high ADCC unit doses were protected. These studies designate specific epitopes recognized by protective antibodies and indicate that protection from the neurologic spread of HSV may be related to neutralization, ADCC, or both. The actual contribution of ADCC and neutralization to in vivo antibody-mediated protection remains unclear.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1846388     DOI: 10.1093/infdis/163.2.263

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  24 in total

1.  Prophylactic and therapeutic effects of human immunoglobulin on the pathobiology of HSV-1 infection, latency, and reactivation in mice.

Authors:  Sarat K Dalai; Lesley Pesnicak; Georgina F Miller; Stephen E Straus
Journal:  J Neurovirol       Date:  2002-02       Impact factor: 2.643

2.  Glycoprotein gI of pseudorabies virus promotes cell fusion and virus spread via direct cell-to-cell transmission.

Authors:  L Zsak; F Zuckermann; N Sugg; T Ben-Porat
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

3.  Acute and latent infection of mice immunised with HSV-1 ISCOM vaccine.

Authors:  M Erturk; T J Hill; C Shimeld; R Jennings
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

4.  Characterization of a type-common human recombinant monoclonal antibody to herpes simplex virus with high therapeutic potential.

Authors:  A De Logu; R A Williamson; R Rozenshteyn; F Ramiro-Ibañez; C D Simpson; D R Burton; P P Sanna
Journal:  J Clin Microbiol       Date:  1998-11       Impact factor: 5.948

5.  Replication of herpes simplex virus type 1 within trigeminal ganglia is required for high frequency but not high viral genome copy number latency.

Authors:  R L Thompson; N M Sawtell
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

6.  Impact of valency of a glycoprotein B-specific monoclonal antibody on neutralization of herpes simplex virus.

Authors:  Adalbert Krawczyk; Jürgen Krauss; Anna M Eis-Hübinger; Martin P Däumer; Robert Schwarzenbacher; Ulf Dittmer; Karl E Schneweis; Dirk Jäger; Michael Roggendorf; Michaela A E Arndt
Journal:  J Virol       Date:  2010-12-01       Impact factor: 5.103

7.  Neutralizing antibodies inhibit axonal spread of herpes simplex virus type 1 to epidermal cells in vitro.

Authors:  Z Mikloska; P P Sanna; A L Cunningham
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

Review 8.  HSV-2: in pursuit of a vaccine.

Authors:  Christine Johnston; David M Koelle; Anna Wald
Journal:  J Clin Invest       Date:  2011-12-01       Impact factor: 14.808

9.  Antibody-mediated protection against genital herpes simplex virus type 2 disease in mice by Fc gamma receptor-dependent and -independent mechanisms.

Authors:  Chin-Fun Chu; Michael G Meador; Christal G Young; Jane E Strasser; Nigel Bourne; Gregg N Milligan
Journal:  J Reprod Immunol       Date:  2007-10-24       Impact factor: 4.054

Review 10.  Herpes simplex virus as a tool to define the role of complement in the immune response to peripheral infection.

Authors:  Mark A Brockman; David M Knipe
Journal:  Vaccine       Date:  2008-12-30       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.